Perrigo to market generic version of Astellas U.S.' Protopic ointment

DUBLIN — Perrigo on Monday announced that it has agreed to market the authorized generic version of Astellas U.S.' Protopic ointment 0.1% and 0.03%. 

 

Protopic ointment (tacrolimus) is indicated to treat moderate to severe eczema. Brand sales were approximately $176 million over the last 52 weeks according to data from Symphony Health Solutions.

 

"This product was the result of the continued hard work and dedication of Perrigo's Rx and Astellas' teams," said Joseph Papa, Perrigo chairman, president and CEO. "This launch is another example of Perrigo's investment and commitment to making quality healthcare more affordable for all consumers across the globe."